- Cybin has acquired Phase 1 N,N-DMT study
- DMT study expected to accelerate the clinical development path of CYB004
- Multiple clinical-stage programs are currently ongoing
- Cybin’s proprietary deuterated DMT molecule designed for the potential treatment of anxiety disorders
- Cybin Inc. is down 6.41 per cent trading at $0.73 per share at close-of-day trading at 4 pm EDT.
Cybin (CYBN) has completed the acquisition of a Phase 1 N, N-dimethyltryptamine (DMT) study from Entheon Biomedical Corp. (CSE:ENBI).
This DMT study, its largest to date, is expected to accelerate the clinical development path of CYB004 – Cybin’s proprietary deuterated DMT molecule for the potential treatment of anxiety disorders, by approximately nine months.
Primary objectives:
- Evaluate the safety of increasing doses of a single dose continuous DMT infusion over 90 minutes
- Characterize the PK of a single dose DMT administered continuously over 90 minutes
- Characterize the PD of a single dose DMT administered continuously over 90 minutes
- And, establish the minimum DMT dose required to produce a psychedelic effect.
Doug Drysdale, CEO of Cybin, commented on the transaction.
“With the closing of this transaction, we are well on our way to advancing CYB004 through Phase 1 development and gathering essential safety and dosing optimization data that will inform the clinical path forward for this important molecule. Cybin now has multiple clinical-stage programs ongoing that we believe will contribute significantly to a greater understanding of the potential of psychedelics to provide therapeutic relief to patients who suffer with a variety of mental health issues.”
Cybin Inc. is down 6.41 per cent trading at $0.73 per share at close-of-day trading at 4 pm EDT.
